(0.06%) 5 249.50 points
(0.04%) 39 656 points
(0.11%) 18 275 points
(0.40%) $78.57
(1.38%) $2.28
(-0.88%) $2 354.10
(-0.46%) $28.38
(0.13%) $1 008.50
(-0.05%) $0.928
(0.21%) $10.86
(0.02%) $0.799
(-0.93%) $91.81
3 days till quarter result
(bmo 2024-05-16)
Expected move: +/- 5.86%
-1.42% INR 562.00
Live Chart Being Loaded With Signals
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics...
Stats | |
---|---|
Today's Volume | 29 434.00 |
Average Volume | 92 785.00 |
Market Cap | 11.26B |
EPS | INR0 ( 2024-02-08 ) |
Next earnings date | ( INR0 ) 2024-05-16 |
Last Dividend | INR1.500 ( 2023-09-15 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 12.90 |
ATR14 | INR0.561 (0.10%) |
Volume Correlation
Lincoln Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lincoln Pharmaceuticals Correlation - Currency/Commodity
Lincoln Pharmaceuticals Financials
Annual | 2022 |
Revenue: | INR5.10B |
Gross Profit: | INR2.69B (52.70 %) |
EPS: | INR36.40 |
FY | 2022 |
Revenue: | INR5.10B |
Gross Profit: | INR2.69B (52.70 %) |
EPS: | INR36.40 |
FY | 2022 |
Revenue: | INR4.68B |
Gross Profit: | INR2.48B (53.06 %) |
EPS: | INR34.63 |
FY | 2021 |
Revenue: | INR4.15B |
Gross Profit: | INR2.16B (52.05 %) |
EPS: | INR31.11 |
Financial Reports:
No articles found.
Lincoln Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR1.500 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR1.500 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR1.000 | 2016-09-23 |
Last Dividend | INR1.500 | 2023-09-15 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | INR11.20 | -- |
Avg. Dividend % Per Year | 0.32% | -- |
Score | 2.18 | -- |
Div. Sustainability Score | 4.60 | |
Div.Growth Potential Score | 5.22 | |
Div. Directional Score | 4.91 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.500 | 0.67% |
2019 | INR1.500 | 0.66% |
2020 | INR1.500 | 0.73% |
2021 | INR1.500 | 0.62% |
2022 | INR1.500 | 0.41% |
2023 | INR1.500 | 0.42% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SPIC.NS | Dividend Junior | 2023-09-20 | Annually | 3 | 0.70% | |
MOTHERSON.NS | Dividend Junior | 2023-08-11 | Annually | 23 | 0.63% | |
HEIDELBERG.NS | Dividend Knight | 2023-09-20 | Annually | 8 | 3.48% | |
BHARTIARTL.NS | Dividend Junior | 2023-08-11 | Annually | 16 | 0.25% | |
RATNAMANI.NS | Dividend Junior | 2023-07-27 | Annually | 19 | 0.72% | |
KOLTEPATIL.NS | Dividend Junior | 2023-08-11 | Annually | 17 | 0.52% | |
EPL.NS | Dividend Junior | 2023-08-04 | Annually | 22 | 1.11% | |
ALICON.NS | Dividend Junior | 2023-09-13 | Annually | 18 | 0.25% | |
SYRMA.NS | No Dividend Player | 2023-09-01 | Insufficient data to determine frequency | 2 | 0.18% | |
NESCO.NS | Dividend Junior | 2023-07-28 | Annually | 17 | 0.40% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.159 | 1.500 | 6.83 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.166 | 1.500 | 9.26 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 47.50 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.34 | 2.00 | 6.55 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.34 | 2.00 | 4.83 | 9.66 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.487 | 1.000 | 5.22 | 5.22 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.182 | 1.000 | 8.35 | 8.35 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 12.92 | 1.000 | 8.80 | 0 | [1 - 100] |
returnOnEquityTTM | 0.166 | 2.50 | 9.53 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.34 | 2.00 | 6.55 | 9.66 | [0 - 30] |
dividendYielPercentageTTM | 0.266 | 1.500 | 3.34 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.34 | 2.00 | 6.55 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 2.53 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0376 | 1.000 | -1.560 | 0 | [0.1 - 0.5] |
Total Score | 5.22 |
Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators